Johanna C. Bendell

Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

h-index83

i10-index350

Publications928

Citations30,876

Grants

No NSF/NIH grants on record.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0031

PageRank within Oncology co-authorship network

Explore collaboration map

Admission Signals

New paper: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer (Nature Communications)2025-05-09
New preprint: Supplementary Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors2025-03-04

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0001-9426-5891

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 4 of 4

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer
Nature Communications · 2025-05-09 · 19 citations
Supplementary Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid TumorsPreprint
2025-03-04
Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid TumorsPreprint
2025-03-04
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Molecular Cancer Therapeutics · 2024-12-05 · 3 citations

Open author page on OpenAlex →